Clinical Trial Update: APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial of APX005M in combination with nivolumab and cabiralizumab in advanced melanoma, non-small cell lung cancer, and renal cell carcinoma has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• APX005M
• Cabiralizumab
• nivolumab (nivolumab)

Snippet

Sponsor: Yale University | Conditions: Advanced Melanoma, Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2023-08-18